AANS Neurosurgeon | Volume 26, Number 4, 2017


Promising Respiratory Drug Focus of New Clinical Trial for Parkinson's Disease

A medication that has been approved to treat various respiratory diseases is now serving as the focal point of a new clinical trial for Parkinson’s disease. This trial is launched as part of the Linked Clinical Trials (LCT) intiative, in collaboration with The Cure Parkinson’s Trust and the Van Andel Research Institute (VARI). “With this trial, we’re moving beyond treating Parkinson’s symptoms. We want to actually slow or stop disease progression,” said Patrik Brundin, MD, PhD, head of LCT’s international scientific committee and director of VARI’s Center for Neurodegenerative Science. “This drug – ambroxol – has performed exceptionally well in preclinical studies for Parkinson’s and is already approved to treat other conditions.” To read more, click here


Winter Clinics for Cranial and Spinal Surgery
Feb. 25, 2018 - Mar. 1, 2018; Snowmass Village, Colo.

69th Southern Neurosurgical Society Annual Meeting
Feb. 28, 2018 - Mar. 3, 2018; San Juan, PR

Second International Brain Mapping Course
April 26-27, 2018; New Orleans

Comments are closed.